Contraceptives are a fast-growing market with $10B+ in global sales. With changing lifestyles in the West, women are opting for careers that result in having children later in life. This combined with increased awareness in developing markets has led to a global rise in contraceptive use. However, third and fourth generation contraceptives are plagued with issues relating to thrombosis.
Navad's estrogen-free contraceptive is well-suited for women with an elevated risk of thrombosis and nursing mothers. It addresses the unmet needs of a global market while delivering a contraceptive efficacy comparable to traditional combined oral contraceptives.